新生儿维生素K注射率下降导致出血风险增加
Infant Bleeding Rises as Newborn Vitamin K Shots Have Fallen
2017年至2025年间,新生儿维生素K注射率从3.1%升至6.8%,导致6个月内出血风险增加47%,脑出血风险翻倍。研究强调维生素K注射的重要性,以预防新生儿出血性疾病。
研究揭示了新生儿维生素K注射率下降与脑出血风险增加之间的关联,为临床决策提供了依据。
— Brain bleed risk more than doubled in infants who missed routine vitamin K shots
by Judy George, Deputy Managing Editor, MedPage Today
November 5, 2026 • 3 min read
- The share of newborns who missed routine vitamin K shots rose to 6.8% in 2025.
- Infants who didn't receive vitamin K shots faced a 47% higher bleeding risk in their first 6 months of life.
- Newborns without vitamin K shots also had doubled intracranial hemorrhage and bleeding-related death risks.
Newborns who missed routine vitamin K shots had higher bleeding risks and more than double the risk of intracranial hemorrhage, a nationwide study of over 5 million infants showed.
Infants who did not receive prophylactic vitamin K shots, the share of which increased from 3.1% in 2017 to 6.8% in 2025, had a 47% higher bleeding risk by 6 months (288.0 vs 185.9 per 10,000; adjusted risk ratio [RR] 1.47, 95% CI 1.43-1.51), reported Heather Burris, MD, MPH, of the Children's Hospital of Philadelphia, and colleagues in JAMA.
They also had more than twice the risks of intracranial bleeding (33.0 vs 13.2 per 10,000; adjusted RR 2.43, 95% CI 2.26-2.62) and death with concurrent bleeding during the birth hospitalization (2.9 vs 1.1 per 10,000; adjusted RR 2.69, 95% CI 2.09-3.47).
Diagnosed vitamin K deficiency tripled in infants and vitamin K deficiency bleeding more than quadrupled during this period, noted Elizabeth Wolf, MD, MPH, of Virginia Commonwealth University in Richmond, and co-authors in a related JAMA Pediatrics research letter.
Among children ages 0 to 6 months, the rate of vitamin K deficiency climbed from 11.8 to 37.3 per 100,000 from 2017 to 2025, while vitamin K deficiency bleeding rose from 24.0 to 107.4 per 100,000.
Brain hemorrhages occurred in 6.9% of infants diagnosed with vitamin K deficiency and 2.4% of those with vitamin K-deficient bleeding.
Both studies leveraged electronic health record data from January 2017 through December 2025 using the Epic Cosmos research platform to evaluate infants born at 35 weeks' gestation or later. The JAMA study followed 5.24 million newborns for the first 6 months of life. The JAMA Pediatrics study evaluated 11 million U.S. infants ages 0 to 6 months who received care from 2017 through 2025.
Vitamin K is required to activate clotting factors II, VII, IX, and X, Wolf and co-authors noted. Newborns can be deficient in vitamin K due to low transplacental transfer, limited gut synthesis, low breast milk concentration, and poor gastrointestinal absorption, they said.
The American Academy of Pediatrics has recommended vitamin K shots since 1961. However, parental rejection of prophylactic vitamin K has increased in recent years, placing more infants at risk for vitamin K deficiency bleeding, Wolf and colleagues observed.
"This study shows the real-world consequences of vitamin K refusal," Wolf told MedPage Today. "Vitamin K-deficient bleeding can be very serious in babies. When the bleeding occurs in the brain, it can result in permanent neurologic damage or even death."
Classical vitamin K deficiency occurs between 2 days and 1 week after birth and leads to umbilical bleeding and bruising. Late vitamin K deficiency occurs between ages 1 week and 6 months and has a 30% to 60% risk of intracranial hemorrhage. Studies have shown that infants without vitamin K shots were 81 times more likely to develop late vitamin K deficiency bleeding.
Temporal trends in the JAMA study showed year-over-year increases in the number of infants with bleeding and these trends differed significantly by vitamin K receipt, noted Laura Kair, MD, MAS, of the University of California Davis School of Medicine in Sacramento, and colleagues in an accompanying editorial.
"While the causes underlying these trends remain uncertain, the authors speculate that maternal-infant dyads may have had more severe medical comorbidities in recent years, and they emphasize that bleeding rates rose significantly faster among those with vitamin K nonreceipt," Kair and colleagues wrote.
"As with all serious but rare outcomes, vitamin K deficiency bleeding risk is a difficult concept to communicate, and when presented as a percentage may seem purely theoretical," the editorialists noted.
"Based on the authors' calculation of number needed to harm, one additional infant would have a bleeding event if just 114 infants did not receive vitamin K," Kair and co-authors pointed out. "This number needed to harm provides a powerful narrative that may be more readily accessible to parents, supporting more effective counseling and decision-making."
Study limitations included reliance on Epic Cosmos data, which excludes infants treated at facilities using other electronic health record systems.
"In countries such as France, Germany, the Netherlands, Switzerland, and Canada, oral vitamin K is offered either routinely or alternatively to intramuscular vitamin K," wrote Wolf and colleagues. "Although the oral form can be less effective in preventing late vitamin K deficiency, a harm-reduction approach that offers oral vitamin K as a second-line alternative may be warranted in the U.S. if rejection of injectable vitamin K continues."
来源:MedPage Today · medpagetoday.com